Summit Creek Advisors LLC Buys New Shares in Artivion, Inc. $AORT

Summit Creek Advisors LLC bought a new stake in Artivion, Inc. (NYSE:AORT) during the 4th quarter, HoldingsChannel.com reports. The fund bought 140,873 shares of the company’s stock, valued at approximately $6,425,000.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Artivion by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares during the period. Bank of America Corp DE grew its position in Artivion by 22.8% during the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock worth $20,062,000 after purchasing an additional 119,634 shares during the period. Invesco Ltd. grew its position in Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after purchasing an additional 139,370 shares during the period. Two Sigma Investments LP grew its position in Artivion by 235.5% during the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after purchasing an additional 313,446 shares during the period. Finally, Kennedy Capital Management LLC grew its position in Artivion by 19.0% during the 3rd quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock worth $18,536,000 after purchasing an additional 70,030 shares during the period. 86.37% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Jean F. Holloway sold 8,962 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total transaction of $340,556.00. Following the sale, the senior vice president directly owned 185,095 shares in the company, valued at $7,033,610. This trade represents a 4.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amy Horton sold 901 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $34,039.78. Following the sale, the chief accounting officer owned 139,088 shares in the company, valued at $5,254,744.64. This trade represents a 0.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 133,043 shares of company stock worth $4,977,158. 6.30% of the stock is currently owned by corporate insiders.

Artivion Price Performance

NYSE:AORT opened at $22.68 on Thursday. Artivion, Inc. has a 52 week low of $19.16 and a 52 week high of $48.25. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $1.10 billion, a PE ratio of 94.49 and a beta of 1.41. The stock’s 50-day moving average price is $33.91 and its 200-day moving average price is $39.88.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Canaccord Genuity Group cut their price target on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, February 20th. LADENBURG THALM/SH SH raised Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target on the stock in a research report on Friday, April 10th. Finally, Citizens Jmp cut their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.83.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.